H. Lundbeck (LUN) Q3 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2024 earnings summary
14 Jan, 2026Executive summary
Revenue grew 13% year-over-year to DKK 16.5 billion in the first nine months of 2024, driven by 21% growth in strategic brands, now 74% of total revenue.
Adjusted EBITDA increased 12% to DKK 5.2 billion with a margin of 31.6%, slightly down due to higher costs and R&D investments.
Net profit rose 18% to DKK 2.6 billion; adjusted net profit and EPS up 8% to DKK 3.9 billion and DKK 3.94.
The company raised the lower end of its full-year 2024 guidance, reflecting confidence in continued performance and the expected Longboard acquisition.
Strong cash flow led to a net cash position of DKK 4.0 billion, with net debt/EBITDA below zero.
Financial highlights
Adjusted gross margin was 88.5%, down 0.8pp due to higher raw material costs, but in line with guidance.
EBIT increased 12% at constant FX to DKK 3,093 million, with margin at 18.8%.
Free cash flow reached DKK 4.13 billion, up 49% year-over-year.
R&D expenses increased 36% due to pipeline progression and a DKK 547 million MAGLI impairment.
Effective tax rate dropped to 16% from 23.5% due to reversal of a prior uncertain tax position.
Outlook and guidance
2024 revenue growth guidance raised to 12–14% at constant FX, with adjusted EBITDA growth at 17–20%.
Adjusted gross margin guided at 88–89%; R&D costs expected at DKK 4.4–4.6 billion, reflecting a DKK 547 million MAGLI impairment.
Net cash position projected to shift to net debt of DKK 12–13 billion due to the Longboard acquisition.
Effective tax rate guided at 13–15%.
Mid-term targets updated: revenue CAGR mid-single digit through 2027, adjusted EBITDA margin above 30%.
Latest events from H. Lundbeck
- Record 2025 growth, 21% dividend hike, board expansion, and focus on innovation and AI.LUN
AGM 202618 Mar 2026 - Raised 2025 guidance after double-digit revenue and profit growth, led by Vyepti and Rexulti.LUN
Q2 202511 Mar 2026 - 13% revenue growth and strong EBITDA in 2025, with robust outlook for 2026.LUN
Q4 20254 Feb 2026 - Q1 2025 revenue up 16%, strategic brands drive growth, and guidance raised for 2025.LUN
Q1 20253 Feb 2026 - Raised 2024 guidance after 10% revenue growth and strong strategic brand performance.LUN
Q2 202423 Jan 2026 - Record results, higher dividend, and robust pipeline progress mark a transformative year.LUN
AGM 202519 Jan 2026 - $2.5–2.6B deal secures a breakthrough DEE asset, fueling long-term growth and pipeline strength.LUN
M&A Announcement19 Jan 2026 - Strategic brands and pipeline advances drive raised growth targets and major capital reallocation.LUN
CMD 202419 Jan 2026 - Upgraded guidance and strong VYEPTI and REXULTI growth reflect innovation-driven momentum.LUN
Jefferies Global Healthcare Conference15 Jan 2026